However, combination treatment with even low concentrations of venetoclax with the IDH2 inhibitor showed significantly reduced DLBCL patient cell survival and increased cleaved Caspase-3/7 activity over that of the compounds alone (Figure 4E,F). The gene discussed is IDH2; the disease is diffuse large B-cell lymphoma.